# A Study in Healthy Men to Find Out How Different Doses of BI 3009947 Are Tolerated and How Different Formulations or Food Influence How BI 3009947 is Taken up Into the Blood

> **NCT07250048** · PHASE1 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 3009947 (Formulation A)
- **DRUG:** BI 3009947 (Formulation B)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07250048
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2025-11-21
- **Primary completion:** 2026-03-02
- **Final completion:** 2026-03-02
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07250048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07250048, "A Study in Healthy Men to Find Out How Different Doses of BI 3009947 Are Tolerated and How Different Formulations or Food Influence How BI 3009947 is Taken up Into the Blood". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07250048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*